DR info

臨床試験数 : 25 / 薬物数 : 35 - (DrugBank : 13) / 標的遺伝子数 : 16 - 標的パスウェイ数 : 22

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

4cc of lidocaïne®
   Centre d'Investigation Clinique et Technologique 805
      2015   -   NCT02455232   France;
9060X
Anatomical Landmark-guided Suprascapular Nerve Block
   Abant Izzet Baysal University
      2022   Phase 4   NCT05260125   Turkey;
Baclofen
   Mustafa Kemal University
      2018   Phase 4   NCT03860662   Turkey;
Balance
   Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
      2020   -   JPRN-UMIN000042549   Japan;
   Otaka Yohei
      2019   -   JPRN-jRCTs042190020   Japan;
   Shanghai Baoshan district Renhe hospital
      2021   -   ChiCTR2000040083   China;
Botox
   Mustafa Kemal University
      2018   Phase 4   NCT03860662   Turkey;
Botulinum toxin
   University of Ioannina
      2020   Phase 1   NCT04630873   Greece;
Botulinum toxin A
   Nanjing Sports Institude
      2014   -   ChiCTR-ICR-15007022   China;
Brivaracetam
   UCB Japan Co., Ltd.
      2019   Phase 3   JPRN-JapicCTI-184137   Japan;
      2017   Phase 3   JPRN-JapicCTI-173687   Japan, Asia except Japan;
      2017   Phase 3   JPRN-JapicCTI-173615   Japan, Asia except Japan;
CO
   Azienda Ospedaliero-Universitaria di Parma
      2021   -   NCT05163210   Italy;
Edonerpic
   FUJIFILM Toyama Chemical Co., Ltd
      2019   Phase 2   JPRN-JapicCTI-194633   Japan;
Gradient
   Waseda University
      2018   -   JPRN-UMIN000035315   Japan;
HC-58
   Asahi Kasei Pharma Corporation
      2012   Phase 2   NCT01623622   Japan;
Lacosamide
   UCB Japan Co., Ltd.
      2016   Phase 3   JPRN-JapicCTI-153104   Japan, Asia except Japan, North America, Europe, Oceania;
      2015   Phase 3   JPRN-JapicCTI-153103   Japan, Asia except Japan, North America, Europe, Oceania;
MEOPA
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 3   NCT00632528   France;
Medicinal air
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 3   NCT00632528   France;
Melatonin
   Hospices Civils de Lyon
      2019   -   NCT04020848   France;
Padsevonil
   UCB Japan Co., Ltd.
      2019   Phase 1   JPRN-JapicCTI-194958   Japan;
Placebo
   UCB Japan Co., Ltd.
      2017   Phase 3   JPRN-JapicCTI-173615   Japan, Asia except Japan;
      2016   Phase 3   JPRN-JapicCTI-153104   Japan, Asia except Japan, North America, Europe, Oceania;
      2015   Phase 3   JPRN-JapicCTI-153103   Japan, Asia except Japan, North America, Europe, Oceania;
SPM927
   UCB Japan Co., Ltd.
      2016   Phase 3   JPRN-JapicCTI-153104   Japan, Asia except Japan, North America, Europe, Oceania;
      2015   Phase 3   JPRN-JapicCTI-153103   Japan, Asia except Japan, North America, Europe, Oceania;
T-817MA
   FUJIFILM Toyama Chemical Co., Ltd
      2019   Phase 2   JPRN-JapicCTI-194633   Japan;
Time delay treatment of botulinum toxin
   University Hospital, Clermont-Ferrand
      2005   Phase 3   NCT00276185   France;
Triheptanoin
   Institut National de la Santé Et de la Recherche Médicale, France
      2015   Phase 2   NCT02408354   France;
Ucb 34714
   UCB Japan Co., Ltd.
      2017   Phase 3   JPRN-JapicCTI-173615   Japan, Asia except Japan;
Ultrasound-guided Suprascapular Nerve Block
   Abant Izzet Baysal University
      2022   Phase 4   NCT05260125   Turkey;
Upper limb muscle block
   Centre d'Investigation Clinique et Technologique 805
      2015   -   NCT02455232   France;